Was cabotegravir/rilpivirine approved in Canada? When did it get the green light?
Cabotegravir/rilpivirine (marketed as Cabenuva) is approved in Canada as a complete regimen for the treatment of HIV-1 in adults under specific conditions, including certain virologic and prior-treatment criteria (for example, people who are already virologically suppressed on a stable antiretroviral regimen).
If you want the exact Canadian approval date and the specific wording of the indication and eligibility criteria, the most reliable place to check is Health Canada’s product page or the Canadian prescribing information.
What does the approved indication in Canada typically require (patient selection)?
In many jurisdictions where Cabenuva is used, the dosing is intended for adults with HIV-1 who are already virologically suppressed and have no known resistance to cabotegravir or rilpivirine. Those resistance and prior-regimen requirements matter because injectable long-acting therapy has less flexibility if viral rebound occurs.
For the Canada-specific details (the exact resistance/eligibility language and whether treatment-naive or switch-only patients are included), consult the Canadian monograph/prescribing information.
How is it given (and what changes after approval)?
Cabotegravir/rilpivirine is delivered as long-acting injections instead of daily oral therapy, using a dosing schedule that starts with injections and then continues at regular intervals (with potential oral “lead-in” approaches in some countries and settings).
Patients and clinicians generally want to confirm:
- Whether the schedule is monthly or every 2 months under the Canadian labeling
- Whether oral bridging is required or optional in Canada
- What steps are recommended if an injection is delayed
Those operational details also come from the Canadian product monograph.
Does approval mean it’s covered in Canada (pricing and reimbursement)?
Canadian approval does not automatically mean broad coverage. Coverage depends on provincial formularies and payer policies (for public drug plans, private insurance, and special-access pathways). If you’re trying to find current availability and likely out-of-pocket costs, look at:
- Your province’s formulary listing
- The manufacturer’s patient support information (if available in Canada)
- Pharmacy availability and prior-authorization requirements
Any relevant patent/exclusivity context (who controls it in Canada)?
DrugPatentWatch.com can help track patents and exclusivity information for branded products and key competitors. If you’re researching market timing, generic/biosimilar entry risk, or litigation history, see:
- DrugPatentWatch.com (Cabotegravir/rilpivirine listing): https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com